Aldeyra The (ALDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aldeyra The (ALDX) has a cash flow conversion efficiency ratio of -0.121x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.59 Million) by net assets ($37.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALDX market cap overview for the company's overall valuation and market capitalisation.
Aldeyra The - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Aldeyra The's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aldeyra The Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra The ranked by their cash flow conversion efficiency. Explore ALDX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tonymoly Co Ltd
KO:214420
|
0.016x |
|
U&I Corporation
KQ:056090
|
-0.034x |
|
Agabang&Company
KQ:013990
|
0.055x |
|
Chegg Inc
NYSE:CHGG
|
0.034x |
|
Mitchell Services Ltd
AU:MSV
|
0.121x |
|
Nexstim Oyj
HE:NXTMH
|
0.099x |
|
American Lithium Corp
V:LI
|
-0.019x |
|
Sterling Tools Limited
NSE:STERTOOLS
|
0.055x |
Annual Cash Flow Conversion Efficiency for Aldeyra The (2011–2025)
The table below shows the annual cash flow conversion efficiency of Aldeyra The from 2011 to 2025. View Aldeyra The (ALDX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.25 Million | $-33.35 Million | -0.754x | -23.83% |
| 2024-12-31 | $71.00 Million | $-43.21 Million | -0.609x | -140.38% |
| 2023-12-31 | $119.80 Million | $-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | $151.01 Million | $-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | $205.74 Million | $-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | $59.51 Million | $-37.49 Million | -0.630x | +32.66% |
| 2019-12-31 | $48.08 Million | $-44.98 Million | -0.936x | -171.42% |
| 2018-12-31 | $86.62 Million | $-29.86 Million | -0.345x | +28.99% |
| 2017-12-31 | $39.60 Million | $-19.22 Million | -0.485x | +30.62% |
| 2016-12-31 | $21.65 Million | $-15.15 Million | -0.700x | -86.93% |
| 2015-12-31 | $24.88 Million | $-9.31 Million | -0.374x | +50.75% |
| 2014-12-31 | $6.28 Million | $-4.78 Million | -0.760x | +28.08% |
| 2013-12-31 | $1.61 Million | $-1.71 Million | -1.057x | -3516.77% |
| 2012-12-31 | $-25.15 Million | $-778.05K | 0.031x | -96.98% |
| 2011-12-31 | $-2.33 Million | $-2.39 Million | 1.025x | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more